{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:15:13Z","timestamp":1775002513695,"version":"3.50.1"},"reference-count":26,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.msard.2025.106705","type":"journal-article","created":{"date-parts":[[2025,8,24]],"date-time":"2025-08-24T14:25:05Z","timestamp":1756045505000},"page":"106705","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Immunosuppression in neuromyelitis optica spectrum disorder: A trial sequential analysis and updated meta-analysis"],"prefix":"10.1016","volume":"103","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-3869-7373","authenticated-orcid":false,"given":"Artur","family":"Menegaz de Almeida","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan D\u2024","family":"Martinez-Lemus","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria Eduarda","family":"Cavalcanti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francisco Cezar Aquino","family":"de Moraes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fernando Westphal","family":"Filho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paulo Robeto Moss","family":"Lopes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"\u00cdtalo Barros","family":"Andrade","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Clara Rocha","family":"Dantas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mariana Rachas","family":"Reis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria I","family":"Reyes-Mantilla","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.msard.2025.106705_bib0025","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.msard.2018.01.001","article-title":"Application of the 2015 diagnostic criteria for neuromyelitis optica spectrum disorders in a cohort of Latin American patients","volume":"20","author":"Carnero Contentti","year":"2018","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"4","key":"10.1016\/j.msard.2025.106705_bib0024","doi-asserted-by":"crossref","first-page":"74","DOI":"10.31083\/j.jin2304074","article-title":"Neuromyelitis optica spectrum disorder in Latin America: state-of-the-art and current challenges","volume":"23","author":"Carnero Contentti","year":"2024","journal-title":"J. Integr. Neurosci."},{"key":"10.1016\/j.msard.2025.106705_bib0029","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.ED000142","article-title":"Updated guidance for trusted systematic reviews: a new edition of the Cochrane Handbook for Systematic Reviews of Interventions. Cochrane Editorial Unit","author":"Cumpston","year":"2019","journal-title":"Cochrane Database Syst. Rev."},{"issue":"24","key":"10.1016\/j.msard.2025.106705_bib0022","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2121804119","article-title":"Rituximab abrogates aquaporin-4-specific germinal center activity in patients with neuromyelitis optica spectrum disorders","volume":"119","author":"Damato","year":"2022","journal-title":"Proc. Natl. Acad. Sci. U. S. A"},{"key":"10.1016\/j.msard.2025.106705_bib0032","article-title":"Immunossuppression in neuromyelitis optica spectrum disorder: a trial sequential analysis and updated meta-analysis","author":"de Almeida MEC","year":"2024","journal-title":"Protoc.io."},{"issue":"4","key":"10.1016\/j.msard.2025.106705_bib0028","doi-asserted-by":"crossref","first-page":"2048","DOI":"10.1007\/s00415-022-11529-6","article-title":"Clinical and epidemiological correlates of treatment change in patients with NMOSD: insights from the circles cohort","volume":"270","author":"Gholizadeh","year":"2023","journal-title":"J. Neurol."},{"issue":"10","key":"10.1016\/j.msard.2025.106705_bib0021","doi-asserted-by":"crossref","first-page":"2025","DOI":"10.1002\/acn3.51451","article-title":"A meta-analysis comparing first-line immunosuppressants in neuromyelitis optica","volume":"8","author":"Giovannelli","year":"2021","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"10.1016\/j.msard.2025.106705_bib0001","doi-asserted-by":"crossref","first-page":"501","DOI":"10.3389\/fneur.2020.00501","article-title":"Epidemiology of neuromyelitis optica spectrum disorder and its prevalence and incidence worldwide","volume":"11","author":"Hor","year":"2020","journal-title":"Front. Neurol."},{"issue":"8","key":"10.1016\/j.msard.2025.106705_bib0011","doi-asserted-by":"crossref","first-page":"2343","DOI":"10.1111\/ene.15355","article-title":"Efficacy and safety of azathioprine, mycophenolate mofetil, and reduced dose of rituximab in neuromyelitis optica spectrum disorder","volume":"29","author":"Huang","year":"2022","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.msard.2025.106705_bib0027","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2020.102652","article-title":"Epidemiological findings of neuromyelitis optica spectrum disorders in a Venezuelan study","volume":"47","author":"Ibis","year":"2021","journal-title":"Mult. Scler. Relat. Disord."},{"issue":"2","key":"10.1016\/j.msard.2025.106705_bib0015","doi-asserted-by":"crossref","first-page":"327","DOI":"10.25259\/JNRP_59_2022","article-title":"Therapeutic response to rituximab in seropositive neuromyelitis optica: experience from a tertiary care center in South India","volume":"14","author":"James","year":"2023","journal-title":"J. Neurosci. Rural. Pract."},{"issue":"9451","key":"10.1016\/j.msard.2025.106705_bib0002","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1016\/S0140-6736(04)17551-X","article-title":"A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis","volume":"364","author":"Lennon","year":"2004","journal-title":"Lancet Lond Engl."},{"issue":"4","key":"10.1016\/j.msard.2025.106705_bib0004","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1084\/jem.20050304","article-title":"IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel","volume":"202","author":"Lennon","year":"2005","journal-title":"J. Exp. Med."},{"issue":"Pt 7","key":"10.1016\/j.msard.2025.106705_bib0003","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1093\/brain\/awf151","article-title":"A role for humoral mechanisms in the pathogenesis of Devic\u2019s neuromyelitis optica","volume":"125","author":"Lucchinetti","year":"2002","journal-title":"Brain J Neurol."},{"key":"10.1016\/j.msard.2025.106705_bib0023","doi-asserted-by":"crossref","DOI":"10.1016\/j.jneuroim.2021.577790","article-title":"Evaluation of effect of empirical attack-preventive immunotherapies in neuromyelitis optica spectrum disorders: an update systematic review and meta -analysis","volume":"363","author":"Ma","year":"2022","journal-title":"J. Neuroimmunol."},{"issue":"4","key":"10.1016\/j.msard.2025.106705_bib0012","article-title":"Updated diagnostic criteria for neuromyelitis optica spectrum disorder: similar outcomes of previously separate cohorts","volume":"4","author":"McCreary","year":"2018","journal-title":"Mult Scler J - Exp Transl Clin."},{"key":"10.1016\/j.msard.2025.106705_bib0030","doi-asserted-by":"crossref","first-page":"b2535","DOI":"10.1136\/bmj.b2535","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"339","author":"Moher","year":"2009","journal-title":"BMJ."},{"issue":"6","key":"10.1016\/j.msard.2025.106705_bib0026","doi-asserted-by":"crossref","first-page":"e1089","DOI":"10.1212\/NXI.0000000000001089","article-title":"Neuromyelitis optica spectrum disorders in Africa: a systematic review","volume":"8","author":"Musubire","year":"2021","journal-title":"Neurol Neuroimmunol Neuroinflammation."},{"issue":"9","key":"10.1016\/j.msard.2025.106705_bib0016","doi-asserted-by":"crossref","first-page":"2003","DOI":"10.1007\/s00415-017-8590-0","article-title":"Comparison of the efficacy of azathioprine and rituximab in neuromyelitis optica spectrum disorder: a randomized clinical trial","volume":"264","author":"Nikoo","year":"2017","journal-title":"J. Neurol."},{"issue":"1","key":"10.1016\/j.msard.2025.106705_bib0014","doi-asserted-by":"crossref","first-page":"3503","DOI":"10.1038\/s41598-024-53838-y","article-title":"Efficacy and safety of rituximab in multiple sclerosis and neuromyelitis optica spectrum disorder","volume":"14","author":"Ongphichetmetha","year":"2024","journal-title":"Sci. Rep."},{"issue":"1","key":"10.1016\/j.msard.2025.106705_bib0033","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1186\/s13643-016-0384-4","article-title":"Rayyan\u2014a web and mobile app for systematic reviews","volume":"5","author":"Ouzzani","year":"2016","journal-title":"Syst. Rev."},{"key":"10.1016\/j.msard.2025.106705_bib0031","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","author":"Page","year":"2021","journal-title":"BMJ."},{"issue":"8","key":"10.1016\/j.msard.2025.106705_bib0013","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1136\/jnnp-2017-315603","article-title":"Immunotherapies in neuromyelitis optica spectrum disorder: efficacy and predictors of response","volume":"88","author":"Stellmann","year":"2017","journal-title":"J. Neurol. Neurosurg. Psychiatry."},{"key":"10.1016\/j.msard.2025.106705_bib0035","doi-asserted-by":"crossref","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","author":"Sterne","year":"2019","journal-title":"BMJ."},{"key":"10.1016\/j.msard.2025.106705_bib0036","doi-asserted-by":"crossref","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"10.1016\/j.msard.2025.106705_bib0034","author":"Takats"}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S221103482500447X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S221103482500447X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T23:19:35Z","timestamp":1774999175000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S221103482500447X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":26,"alternative-id":["S221103482500447X"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2025.106705","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immunosuppression in neuromyelitis optica spectrum disorder: A trial sequential analysis and updated meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2025.106705","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"106705"}}